

Media Release

Dr. Nicolas Meyer succeeds Dr. Beat Maurer on the Executive Board

Burgdorf, 30.03.2023, 7 a.m. – Ypsomed (SIX: YPSN) announces a change in its Executive Board. After more than thirty years with Ypsomed and formerly Disetronic, Dr Beat Maurer will retire as Chief Legal Officer (CLO) on 31 March 2023. He will be succeeded by Dr Nicolas Meyer, who will take up the position as CLO at Ypsomed on 01 May 2023.

Beat Maurer has been with Ypsomed (formerly Disetronic) since 1992 and led the legal department for decades. He was also Secretary to the Board of Directors. In addition to his work at Ypsomed, Beat Maurer has been a judge specializing in issues relating to business law and intellectual property law at the Commercial Court of the Canton of Berne since 2002. He is also President of Swiss Medtech's "Legal & Compliance" Group.

"Beat Maurer has reliably accompanied our company and my family for decades. He has always shown calm and prudence in the face of all the challenges and changes in our long, shared history. With great competence and thoughtfulness, he has mastered some fundamental changes with us. Thanks to his achievements, we are well positioned for the future, for which we are very grateful and wish him all the best from the bottom of our hearts. At the same time, I am pleased that we were able to win Nicolas Meyer as his successor. He prevailed in an outstanding field of candidates and we welcome him warmly", comments CEO Simon Michel on the change in the Executive Board.

Dr Nicolas Meyer was General Counsel at the EMS Group for nine years and has spent the past three years as General Counsel at RUAG, where his responsibilities included managing the break-up of the Group. Prior to that, he worked for around ten years as a lawyer at Lenz Caemmerer in Basel. Nicolas Meyer received his PhD in intellectual property law in 2004 and his Master of Law degree from the University of Basel in 1997.

Contact

Susanne Köhler, Public Relations, Ypsomed Holding AG
+41 34 424 47 32, susanne.koehler@ypsomed.com

Ypsomed Group

Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years of experience. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brands mylife Diabetescare directly to patients or via pharmacies and hospitals as well as under YDS Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. The company is headquartered in Burgdorf, Switzerland, and has a global network of production facilities, subsidiaries and distribution partners employing a staff of over 2,000 employees worldwide.